Results 241 to 250 of about 106,174 (376)

AAV9-cBIN1 gene therapy rescues chronic heart failure due to ischemic cardiomyopathy in a canine model. [PDF]

Commun Med (Lond)
Khan MS, Smego D, Li J, Ishidoya Y, Offei E, Ruiz Castillo MS, Hirahara AM, Balmaceda P, Hunter J, Athavale A, Revelo MP, Palatinus JA, Selzman CH, Ranjan R, Hong T, Dosdall DJ, Shaw RM.   +16 more
europepmc   +1 more source

Simultaneous endocardial and epicardial microelectrode catheter mapping in patients with non ischemic cardiomyopathy and refractory sustained ventricular tachycardia Angelo A. V. de Paola, Ge�rgia G. Silva, Luiz R. Leite, Roberto L. Farias, Almino Rocha Neto. Federal University of S�o Paulo - Paulista School of Medicine, S�o Paulo, Brazil

, 2001

openalex   +1 more source

Collagen propeptide as predictors for weaning from mechanical cardiac support in patients with non-ischemic dilated cardiomyopathy [PDF]

, 2003
Johannes Mueller, Hong Liang, Sabine Bartel, Gert Wallukat, Yuguo Weng, D. Kemper, Thorsten Drews, Michael Dandel, M Jurmann, Roland Hetzer   +9 more
openalex   +1 more source

Hypertrophic cardiomyopathy in the young: Another form of ischemic cardiomyopathy?

Journal of the American College of Cardiology, 1993
Michael W. Dae, Stanford Ewing, Rajagopal Krishnan, Elias H. Botvinick   +3 more
openaire   +3 more sources

Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure

European Journal of Heart Failure, EarlyView.
Heart failure (HF) with supranormal ejection fraction (HFsnEF) is an unnoticed but emerging entity in HF. This study showed that HFsnEF carries a similarly increased cardiovascular risk as HF with reduced ejection fraction (HFrEF) and distinct structural and proteomic characteristics from HFrEF, warranting a further comprehensive understanding and ...
Yasuhiko Sakata, Kotaro Nochioka, Satoshi Yasuda, Koichi Ishida, Takashi Shiroto, Jun Takahashi, Shintaro Kasahara, Ruri Abe, Shinsuke Yamanaka, Takahide Fujihashi, Hideka Hayashi, Shintaro Kato, Katsunori Horii, Kanako Teramoto, Tsutomu Tomita, Satoshi Miyata, Koichiro Sugimura, Iwao Waga, Masao Nagasaki, Hiroaki Shimokawa   +19 more
wiley   +1 more source

Long-Term Clinical Outcomes in Patients With Transthyretin Cardiac Amyloidosis Versus Non-Ischemic Cardiomyopathy. [PDF]

Cardiol Res
Okeke BC, Chrusciel T, Benjamin MM.
europepmc   +1 more source

Impact of gender on the improvement in left ventricular systolic function following coronary artery bypass graft surgery for ischemic cardiomyopathy Mohammad Bashir, Imran Afridi, Ibrahim Abdalla, Nicholas G. Smedira, Eugene Blackstone, Michael S. Lauer. The Cleveland Clinic Foundation, Cleveland, OH

, 2001

openalex   +1 more source

673 Can resting 2D echocardiography identify patients with ischemic cardiomyopathy and low likelihood of functional improvement after revascularization? [PDF]

, 2003
Vittoria Rizzello, Elena Biagini, Alfred H. Schinkel, Jeroen J. Bax, Manolis Bountioukos, Eleni C. Vourvouri, J.R.T.C. Roelandt, Don Poldermans   +7 more
openalex   +1 more source

ISCHEMIC CAUSE OF NONISCHEMIC CARDIOMYOPATHY

Journal of the American College of Cardiology, 2021
Maryam Saleem, Zachary Ahart, Khalil Anouti, Obadah Aqtash, Pooneh Nabavizadeh, Erica Pivato, Fahad Waqar   +6 more
openaire   +2 more sources

Cancer therapy‐related cardiotoxicity is associated with distinct alterations of the myocardial lipidome

European Journal of Heart Failure, EarlyView.
Lipidome changes in anthracycline‐induced cardiotoxicity (AIC). Aims Anthracyclines are key components of various chemotherapy regimens, but their clinical utility is limited by severe cardiotoxic side effects. Previous studies have suggested that anthracycline‐induced cardiotoxicity (AIC) may be driven by alterations in myocardial lipid metabolism ...
Vera M. Braun, Anna Foryst‐Ludwig, Ulf Landmesser, István Baczkó, Hendrik Milting, Ulrich Kintscher, Niklas Beyhoff   +6 more
wiley   +1 more source